
-
Cambodia hails opening of naval base renovated by China
-
Verstappen snatches 'insane' pole for Japan GP in track record
-
Thousands rally for South Korea's impeached ex-president Yoon
-
New Zealand hammer Pakistan by 43 runs to sweep ODI series 3-0
-
Myanmar quake death toll passes 3,300: state media
-
India's Modi in Sri Lanka for defence and energy deals
-
'No one to return to': Afghans fear Pakistan deportation
-
Fractious Republicans seek unity over Trump tax cuts
-
America's passion for tariffs rarely pays off, economists warn
-
Trump's global tariff takes effect in dramatic US trade shift
-
North Korea's Kim fires new sniper rifle while visiting troops
-
Norris fastest in McLaren 1-2 as fires again disrupt Japan GP practice
-
Vital European defence startups still facing hurdles
-
'I don't have a voice in my head': Life with no inner monologue
-
Pakistan chasing 265 to win shortened third New Zealand ODI
-
US soybeans, energy: Who is hit by China's tariff retaliation?
-
Green, Sengun lift Rockets over Thunder, Celtics clinch record
-
Ariya downs defending champ Korda to advance at LPGA Match Play
-
Ovechkin ties Gretzky's all-time record of 894 NHL goals
-
Under-pressure Doohan vows to learn from Japanese GP smash
-
Harman goes four clear at Texas Open
-
McLaughlin-Levrone, Thomas cruise to wins at opening Grand Slam Track
-
Russian strike kills 18 in Ukrainian president's home city
-
US cardinal defrocked for sex abuse dies at 94
-
Lula admits 'still a lot to do' for Indigenous Brazilians
-
England, Germany and Spain on mark in women's Nations League
-
Bayern's Musiala to miss Inter first leg with injury
-
Judge orders return to US of Salvadoran man deported in error
-
'Class' Freeman eases Northampton past Clermont and into Champions Cup quarters
-
Amadou of Malian blind music duo dies aged 70
-
Freeman hat-trick eases Northampton into Champions Cup quarters with Clermont win
-
Defiant Trump dismisses stock market's tariff plunge
-
Musiala injury sours Bayern win at Augsburg
-
Peruvian schoolkids living in fear of extortion gangs
-
Top seed Pegula rallies to oust defending champ Collins in Charleston
-
Amadou of Malian blind music duo Amadou & Mariam dies aged 70
-
California to defy Trump's tariffs to allay global trade fears
-
Bayern's Musiala subbed off with injury days out from Inter clash
-
Russian strike kills 16 in Ukraine leader's home city, children among dead
-
NBA fines Grizzlies' Morant for imaginary gun gesture
-
Trump tariffs offer opportunity for China
-
UK comedian Russell Brand charged with rape
-
Marsh, Markram help Lucknow edge Mumbai in IPL
-
Trump gives TikTok extra 75 days to find buyer
-
Israel attorney general accuses PM of 'conflict of interest' in security chief dismissal
-
Emery glad to see Rashford make landmark appearance
-
Sean 'Diddy' Combs faces more charges ahead of criminal trial
-
Russian missile strike kills 14 in Ukraine leader's home city
-
Trump's tariff Big Bang puts global economy under threat
-
I Am Maximus backed for National as Mullins hot streak continues
RBGPF | 100% | 69.02 | $ | |
BCE | 0.22% | 22.71 | $ | |
NGG | -5.25% | 65.93 | $ | |
CMSC | 0.13% | 22.29 | $ | |
GSK | -6.79% | 36.53 | $ | |
RELX | -6.81% | 48.16 | $ | |
AZN | -7.98% | 68.46 | $ | |
BCC | 0.85% | 95.44 | $ | |
RIO | -6.88% | 54.67 | $ | |
SCS | -0.56% | 10.68 | $ | |
BTI | -5.17% | 39.86 | $ | |
JRI | -7.19% | 11.96 | $ | |
RYCEF | -18.79% | 8.25 | $ | |
VOD | -10.24% | 8.5 | $ | |
CMSD | 0.7% | 22.83 | $ | |
BP | -10.43% | 28.38 | $ |

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications
Ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors
Strategic focus on exploratory investigator-initiated studies with institutional partners
Ended the quarter with $6.8 million of cash to fund operations
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications
Ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors
Strategic focus on exploratory investigator-initiated studies with institutional partners
Ended the quarter with $6.8 million of cash to fund operations
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of 2024.

"Over the course of the past quarter, we have continued to make progress advancing our DNase platform. Our focus is to leverage institutional partnerships to drive our development strategy, such as our recently announced agreement with Tokyo Medical University and extension of our agreement with The Scripps Research Institute, efficiently utilizing our capital while minimizing our non-program cash spend. We are encouraged by the preclinical data generated to date and remain focused on building a growing body of data and further developing our pipeline to build value in the near and long term," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
Xenetic continues to advance its DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preliminary preclinical studies evaluating the combinations of DNase I with chemotherapy and DNase I with immuno-therapies in colorectal cancer models as well as CAR-T therapy have been completed. The Company and its partners plan to report further preclinical data at scientific conferences as it recently did at the Society for Immunotherapy of Cancer (SITC) conference (SITC 2024).
Summary of Financial Results for Third Quarter 2024
Net loss for the quarter ended September 30, 2024 was approximately $0.4 million. Research & development expenses for the three months ended September 30, 2024 decreased by approximately $0.7 million, or 63.9% to approximately $0.4 million from approximately $1.0 million in the comparable quarter in 2023. The decrease was primarily due to decreased spending in connection with our process development efforts related to our DNase platform. General and administrative expenses for the three months ended September 30, 2024 was relatively flat with the three months ended September 30, 2023. Increases in legal fees during the three months ended September 30, 2024 compared to the same period in 2023 were offset by decreases in personnel costs during the third quarter due to the departure of our former Chief Executive Officer in the second quarter of 2024.
The Company ended the quarter with approximately $6.8 million of cash.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications, ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors, our strategic focus on exploratory investigator-initiated studies with institutional partners, including leveraging institutional partnerships to drive our development strategy, our focus on advancing innovative immune-oncology technologies addressing hard to treat cancers, our expectations regarding preclinical data generated to date, our focus on building a growing body of data and further developing our pipeline to build value in the near and long term, our plans regarding presentations of the results of preclinical data, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program towards Phase 1 clinical development as an adjunctive therapy for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
F.Dubois--AMWN